



## Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018

February 22, 2018

CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial results, business highlights and 2018 financial guidance.

What: Vericel Corporation Fourth-Quarter 2017 Earnings Call

When: Monday, March 5, 2018 at 8:30am (EST)

Where: <http://investors.vcel.com/events-presentations?>

How: The conference call will be available live in the Investors section of the Vericel website at <http://investors.vcel.com/events-presentations?>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.

To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2017 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate in the live call, the webcast will be available at <http://investors.vcel.com/events-presentations?> until March 5, 2019. A replay of the call will also be available until 11:30am (EST) on March 10, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 4899311.

### About Vericel Corporation

Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. Vericel is marketing MACI<sup>®</sup> (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel<sup>®</sup> (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup> and MACI<sup>®</sup> are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

### Global Media Contacts:

David Schull  
Russo Partners LLC  
+1 212-845-4271 (office)  
+1 858-717-2310 (mobile)  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)

Karen Chase  
Russo Partners LLC  
+1 646-942-5627 (office)  
+1 917-547-0434 (mobile)  
[Karen.chase@russopartnersllc.com](mailto:Karen.chase@russopartnersllc.com)

### Investor Contacts:

Chad Rubin  
The Trout Group  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1 (646) 378-2947

Lee Stern  
The Trout Group  
[lstern@troutgroup.com](mailto:lstern@troutgroup.com)  
+1 (646) 378-2922

[Primary Logo](#)

Source: Vericel Corporation